BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
$9.94
मूल्य · अग 19, 2026
मौलिकता इस प्रकार है अग 5, 2026
52W रेंज
$6–$11
75% of range
विश्लेषक रेटिंग
BUY
17 analysts
मूल्य लक्ष्य
$21
+109% upside
P/E (TTM)
9.8
ROE
-97.6%
शुद्ध लाभ मार्जिन
30.2%
BioCryst Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
और पढ़ें
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
BCRX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$9.94
मार्केट कैप
$2.52B
P/E (TTM)
9.8
EPS (TTM)
$1.21
राजस्व (TTM)
$875M
लाभांश प्रतिफल
—
ROE
-97.6%
D/E ऋण/इक्विटी
0.0
52W रेंज
$6 – $11
BCRX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
Configure
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व और शुद्ध आय
$875M
2016-12-31
→
2025-12-31
EPS
$1.21
2020-12-31
→
2025-12-31
फ्री कैश फ्लो
$345M
2016-12-31
→
2025-12-31
मार्जिन
30.2%
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
मेट्रिक
5Y रुझान
BCRX
सहकर्मी माध्यिका
P/E (TTM)
9.8
97.6
P/S (TTM)
2.9
7.7
P/B
-21.2
8.0
EV / EBITDA
6.6
—
Price / FCF (मूल्य / FCF)
7.3
—
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
मेट्रिक
5Y रुझान
BCRX
सहकर्मी माध्यिका
Operating Margin (परिचालन मार्जिन)
39.0%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
30.2%
-51.7%
ROA
52.5%
-44.2%
ROE
-97.6%
-63.5%
ROIC
-282.4%
—
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
मेट्रिक
5Y रुझान
BCRX
सहकर्मी माध्यिका
Debt / Equity (ऋण / इक्विटी)
0.0
18.7
Current Ratio (वर्तमान अनुपात)
2.1
4.9
Quick Ratio (त्वरित अनुपात)
1.9
—
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
मेट्रिक
5Y रुझान
BCRX
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
94.1%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
47.8%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
117.9%
—
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
मेट्रिक
5Y रुझान
BCRX
सहकर्मी माध्यिका
BCRX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
खरीदें
17 विश्लेषक
- मजबूत खरीद 5 29.4%
- खरीदें 10 58.8%
- होल्ड 2 11.8%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
11 विश्लेषक · 2026-08-17
मध्यिका
$17.00
माध्य
$20.82
← सभी लक्ष्यों से नीचे
$9.94
निम्न
$12.00
उच्च
$32.00
मध्यिका लक्ष्य
$17.00
+71.0%
माध्य लक्ष्य
$20.82
+109.4%
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
0.02%
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $0.30 | $0.12 | 0.18% |
| 31 मार्च 2026 | $-0.09 | $0.05 | -0.14% |
| 31 दिसमबर 2025 | $0.01 | $0.04 | -0.03% |
| 30 सितमबर 2025 | $0.06 | $0.04 | 0.02% |
| 30 जून 2025 | $0.04 | $0.01 | 0.03% |
| 31 मार्च 2025 | $0.00 | $-0.07 | 0.07% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | — |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | — |
| SLS | $577M | -15.1 | — | — | -55.4% | — |
| RARE | $2.22B | -3.9 | 20.2% | -85.4% | -1613.2% | — |
| KOD | $1.73B | -6.5 | — | — | -202.0% | — |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | — |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | — |
| COAG | — | — | — | — | — | — |
| MLYS | $2.96B | -15.8 | — | — | -32.2% | — |
| KLRA | — | — | — | — | — | — |
| VERA | — | -10.9 | — | — | -55.9% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
बैलेंस शीट 27
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
नकदी प्रवाह 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
विकास दरें 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 13
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
आय विवरण 16
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | -418,684,000 | 210,176,000 | 209,519,000 | 208,882,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | -436,451,000 | 219,885,000 | 219,886,000 | 215,261,000 | -412,698,000 | 206,905,000 | 206,425,000 | 206,064,000 | -375,073,000 | 189,644,000 | 189,118,000 | 188,509,000 | -370,775,000 | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
बैलेंस शीट 24
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
नकदी प्रवाह 14
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
मूल्यांकन (TTM) 13
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $697M | $625M | · | $585M | $535M | $465M | · | $406M | $371M | $331M | · | $314M | $293M | $260M | · | $232M | |
| Net Income TTM | $-625M | $-704M | · | $4M | $-22M | $-62M | · | $-98M | $-160M | $-200M | · | $-207M | $-230M | $-229M | · | $-234M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -3.8 | -3.3 | · | 759.0 | -81.5 | -25.0 | · | -15.5 | -7.5 | -4.9 | · | -6.4 | -5.7 | -6.8 | · | -9.8 | |
| P/S | 3.7 | 3.9 | · | 2.7 | 3.5 | 3.4 | · | 3.9 | 3.4 | 3.2 | · | 4.3 | 4.6 | 6.1 | · | 10.1 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| P / FCF | · | -38.9 | · | · | · | -56.7 | · | · | · | -19.4 | · | · | · | -33.0 | · | · | |
| EV / EBITDA | 26.4 | -3.7 | · | 53.4 | 62.6 | 73.7 | · | 232.9 | 172.6 | -89.7 | · | -125.1 | -71.5 | -59.0 | · | -133.3 | |
| EV / FCF | · | -41.4 | · | · | · | -57.5 | · | · | · | -23.6 | · | · | · | -34.7 | · | · | |
| EV / Revenue | 3.7 | 4.1 | · | 2.7 | 3.5 | 3.4 | · | 4.4 | 4.1 | 3.8 | · | 4.8 | 5.1 | 6.4 | · | 10.0 | |
| Earnings Yield | -26.0% | -30.5% | · | 0.13% | -1.2% | -4.0% | · | -6.5% | -13.3% | -20.5% | · | -15.5% | -17.5% | -14.8% | · | -10.2% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $875M | $451M | $331M | $271M | $157M |
| परिचालन मार्जिन % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| शुद्ध आय | $264M | $-89M | $-227M | $-247M | $-184M |
| तनुकरणित EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| वर्तमान अनुपात | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| त्वरित अनुपात | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $345M | $-53M | $-97M | $-163M | $-145M |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
📊
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 347 फाइलर्स · $2.1B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 63 (-13 पिछली तिमाही की तुलना में) | 34 (-5 पिछली तिमाही की तुलना में) | 130 (+18 पिछली तिमाही की तुलना में) | 83 (+1 पिछली तिमाही की तुलना में) | +46K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $158271860 | 15827186 | 7.51% | शेयर |
| STATE STREET CORP | $151910980 | 15191098 | 7.21% | शेयर |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150964030 | 15096403 | 7.16% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $113642360 | 11364236 | 5.39% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111391580 | 11139158 | 5.28% | शेयर |
| TCG Crossover Management, LLC | $110209680 | 11020968 | 5.23% | शेयर |
| PERCEPTIVE ADVISORS LLC | $103088880 | 10308888 | 4.89% | शेयर |
| JANUS HENDERSON GROUP PLC | $83961589 | 8814865 | 3.98% | शेयर |
| Vestal Point Capital, LP | $83000000 | 8300000 | 3.94% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $67753490 | 6775349 | 3.21% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $53581572 | 5356880 | 2.54% | शेयर |
| Aberdeen Group plc | $53108710 | 5310871 | 2.52% | शेयर |
| Frazier Life Sciences Management, L.P. | $40092400 | 4009240 | 1.90% | शेयर |
| GOLDMAN SACHS GROUP INC | $35393210 | 3539321 | 1.68% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $33947290 | 3394729 | 1.61% | शेयर |
| TWO SIGMA ADVISERS, LP | $31895074 | 4089112 | 1.51% | शेयर |
| RP Management, LLC | $28846155 | 3846154 | 1.37% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $27161110 | 2716111 | 1.29% | शेयर |
| Fisher Asset Management, LLC | $26040270 | 2604027 | 1.24% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $25302900 | 2530290 | 1.20% | शेयर |
| Kynam Capital Management, LP | $25226600 | 2522660 | 1.20% | शेयर |
| Candriam S.C.A. | $25125293 | 2514949 | 1.19% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23532910 | 2353291 | 1.12% | शेयर |
| RICE HALL JAMES & ASSOCIATES, LLC | $23320430 | 2332043 | 1.11% | शेयर |
| AQR CAPITAL MANAGEMENT LLC | $21850110 | 2185011 | 1.04% | शेयर |
| Nantahala Capital Management, LLC | $19011600 | 1901160 | 0.90% | शेयर |
| Eversept Partners, LP | $18656530 | 1865653 | 0.88% | शेयर |
| ORBIMED ADVISORS LLC | $18520000 | 1852000 | 0.88% | शेयर |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18449120 | 1844912 | 0.88% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $17595730 | 1759573 | 0.83% | शेयर |
| CITADEL ADVISORS LLC | $17591600 | 1759160 | 0.83% | शेयर |
| IMC-Chicago, LLC | $16343360 | 1634336 | 0.78% | शेयर |
| Parkman Healthcare Partners LLC | $16242790 | 1624279 | 0.77% | शेयर |
| JANE STREET GROUP, LLC | $14267680 | 1426768 | 0.68% | शेयर |
| OP Asset Management Ltd | $13409900 | 1340990 | 0.64% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11956510 | 1195651 | 0.57% | शेयर |
| Pictet Asset Management Holding SA | $11951392 | 1249771 | 0.57% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $11740520 | 1174052 | 0.56% | शेयर |
| FIRST TRUST ADVISORS LP | $11204690 | 1120469 | 0.53% | शेयर |
| JANE STREET GROUP, LLC | $9944130 | 994413 | 0.47% | कॉल ऑप्शन |
| Cubist Systematic Strategies, LLC | $9462419 | 1246696 | 0.45% | शेयर |
| MOORE CAPITAL MANAGEMENT, LP | $8483360 | 848336 | 0.40% | शेयर |
| FMR LLC | $8062330 | 806233 | 0.38% | शेयर |
| BANK OF AMERICA CORP /DE/ | $7754020 | 775402 | 0.37% | शेयर |
| ExodusPoint Capital Management, LP | $7449170 | 744917 | 0.35% | शेयर |
| Man Group plc | $7324800 | 732480 | 0.35% | शेयर |
| Rosalind Advisors, Inc. | $7215040 | 721504 | 0.34% | शेयर |
| Schonfeld Strategic Advisors LLC | $7108160 | 710816 | 0.34% | शेयर |
| BlackRock, Inc. | $5984400 | 598440 | 0.28% | शेयर |
| Elmind Capital, LP | $5200000 | 520000 | 0.25% | शेयर |
| Bridgewater Associates, LP | $4910570 | 491057 | 0.23% | शेयर |
| NAN FUNG TRINITY (HK) LTD | $4500000 | 450000 | 0.21% | शेयर |
| SPHERA FUNDS MANAGEMENT LTD. | $4220510 | 422051 | 0.20% | शेयर |
| Swiss National Bank | $4152680 | 415268 | 0.20% | शेयर |
| Susquehanna Portfolio Strategies, LLC | $4047040 | 404704 | 0.19% | शेयर |
| DAFNA Capital Management LLC | $4002480 | 400248 | 0.19% | शेयर |
| Hudson Bay Capital Management LP | $4000000 | 400000 | 0.19% | शेयर |
| Aquatic Capital Management LLC | $3628950 | 362895 | 0.17% | शेयर |
| DOLIVER CAPITAL ADVISORS, INC. | $3563603 | 374328 | 0.17% | शेयर |
| Assenagon Asset Management S.A. | $3530440 | 353044 | 0.17% | शेयर |
| Kodai Capital Management LP | $3515993 | 468799 | 0.17% | शेयर |
| MACKENZIE FINANCIAL CORP | $3472990 | 347299 | 0.16% | शेयर |
| CITIGROUP INC | $3467520 | 346752 | 0.16% | शेयर |
| Phocas Financial Corp. | $3405410 | 340541 | 0.16% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $3238000 | 323800 | 0.15% | कॉल ऑप्शन |
| ALPS ADVISORS INC | $3179600 | 317960 | 0.15% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $3121694 | 327909 | 0.15% | शेयर |
| RHUMBLINE ADVISERS | $2798390 | 279839 | 0.13% | शेयर |
| Rafferty Asset Management, LLC | $2656180 | 265618 | 0.13% | शेयर |
| Point72 Asset Management, L.P. | $2609170 | 260917 | 0.12% | शेयर |
| Nuveen, LLC | $2599030 | 259903 | 0.12% | शेयर |
| NFJ INVESTMENT GROUP, LLC | $2568330 | 256833 | 0.12% | शेयर |
| Nebula Research & Development LLC | $2567121 | 286509 | 0.12% | शेयर |
| WINTON GROUP Ltd | $2556000 | 255600 | 0.12% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $2459444 | 258345 | 0.12% | शेयर |
| MARTINGALE ASSET MANAGEMENT L P | $2425080 | 242508 | 0.12% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $2324670 | 232467 | 0.11% | शेयर |
| CITADEL ADVISORS LLC | $2322000 | 232200 | 0.11% | कॉल ऑप्शन |
| IEQ CAPITAL, LLC | $2274210 | 227421 | 0.11% | शेयर |
| Bank of New York Mellon Corp | $2251670 | 225167 | 0.11% | शेयर |
| D. E. Shaw & Co., Inc. | $2249120 | 224912 | 0.11% | शेयर |
| JUPITER ASSET MANAGEMENT LTD | $2221030 | 222103 | 0.11% | शेयर |
| HUSSMAN STRATEGIC ADVISORS, INC. | $2100000 | 210000 | 0.10% | शेयर |
| PFM Health Sciences, LP | $2073570 | 207357 | 0.10% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $1962800 | 196280 | 0.09% | शेयर |
| TUDOR INVESTMENT CORP ET AL | $1951280 | 195128 | 0.09% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1853000 | 185300 | 0.09% | पुट ऑप्शन |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $1820161 | 233354 | 0.09% | शेयर |
| Engineers Gate Manager LP | $1750020 | 175002 | 0.08% | शेयर |
| Squarepoint Ops LLC | $1747140 | 174714 | 0.08% | शेयर |
| QTR Family Wealth, LLC | $1610820 | 161082 | 0.08% | शेयर |
| Gotham Asset Management, LLC | $1564210 | 156421 | 0.07% | शेयर |
| CITADEL ADVISORS LLC | $1450000 | 145000 | 0.07% | पुट ऑप्शन |
| Corient Private Wealth LP | $1429860 | 142986 | 0.07% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $1386570 | 138657 | 0.07% | शेयर |
| Quantinno Capital Management LP | $1374530 | 137453 | 0.07% | शेयर |
| MetLife Investment Management, LLC | $1356700 | 135670 | 0.06% | शेयर |
| PROFUND ADVISORS LLC | $1340340 | 134034 | 0.06% | शेयर |
| Virtus Investment Advisers, LLC | $1336640 | 133664 | 0.06% | शेयर |
| ADAR1 Capital Management, LLC | $1330000 | 133000 | 0.06% | शेयर |
कंपनी के अंदरूनी सूत्र 51 इनसाइडर्स · 21 अधिकारी · 30 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 दिसमबर 2025 A | 268700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 दिसमबर 2024 A | 377867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 फ़रवरी 2020 A | 125176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 मार्च 2011 M | 57102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 दिसमबर 2025 M | 952583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 मार्च 2008 A | 65730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 मई 2026 M | 400703 | 0 | 7 | $-3461969 |
| Sandeep Menon | Chief R&D Officer | 6 अप्रैल 2026 A | 205150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 मार्च 2025 F | 377318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 दिसमबर 2022 A | 16653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 नवमबर 2022 M | 298541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 मार्च 2022 M | 37954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 दिसमबर 2020 A | 45000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 जनवरी 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 मार्च 2012 F | 24124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 फ़रवरी 2011 A | 9766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 मार्च 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 जुलाई 2008 P | 3048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 जुलाई 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 जुलाई 2007 P | 3659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 मई 2007 A | 1928 | 0 | 0 | $0 |
| Amy E Mckee | निदेशक | 11 जून 2026 A | 47177 | 0 | 1 | $-100285 |
| Theresa Heggie | निदेशक | 11 जून 2026 A | 80646 | 0 | 1 | $-504823 |
| Machelle Sanders | निदेशक | 11 जून 2026 A | 45936 | 0 | 1 | $-68544 |
| Jill C. Milne | निदेशक | 11 जून 2026 A | 31938 | 0 | 0 | $0 |
| Steven Frank | निदेशक | 11 जून 2026 A | 35459 | 0 | 0 | $0 |
| Steven K Galson | निदेशक | 11 जून 2026 A | 27794 | 0 | 0 | $0 |
| Jon P Stonehouse | निदेशक | 11 जून 2026 A | 1339775 | 0 | 0 | $0 |
| Vincent Milano | निदेशक | 11 जून 2026 A | 108483 | 0 | 0 | $0 |
| Alan G Levin | निदेशक | 11 जून 2026 A | 79565 | 0 | 0 | $0 |
| Nancy J Hutson | निदेशक | 12 जून 2025 A | 99138 | 0 | 0 | $0 |
| George B Abercrombie | निदेशक | 12 जून 2024 A | 36431 | 0 | 0 | $0 |
| Steve Aselage | निदेशक | 12 जून 2024 A | 70159 | 0 | 0 | $0 |
| Kenneth B Lee JR | निदेशक | 13 जून 2023 A | 68863 | 0 | 0 | $0 |
| Robert Alexander Ingram | निदेशक | 28 फ़रवरी 2023 A | 100198 | 0 | 0 | $0 |
| Stanley C Erck | निदेशक | 28 नवमबर 2018 M | 48333 | 0 | 0 | $0 |
| Fred Cohen | निदेशक | 20 जून 2018 A | 119410 | 0 | 0 | $0 |
| Sanj K Patel | निदेशक | 24 मई 2017 A | — | 0 | 0 | $0 |
| Charles A Sanders | निदेशक | 29 फ़रवरी 2016 A | 12971 | 0 | 0 | $0 |
| Peder Jensen | निदेशक | 2 मई 2014 A | 60000 | 0 | 0 | $0 |
| John L Higgins | निदेशक | 23 मई 2012 A | — | 0 | 0 | $0 |
| HOROVITZ ZOLA P | निदेशक | 23 मई 2012 A | 3000 | 0 | 0 | $0 |
| Stephen R Biggar | निदेशक | 12 मई 2011 A | — | 0 | 0 | $0 |
| Beth C Seidenberg | निदेशक | 13 मई 2010 A | 3000 | 0 | 0 | $0 |
| William W Featheringill | निदेशक | 13 मई 2010 A | 231538 | 0 | 0 | $0 |
| William M Spencer III | निदेशक | 16 मई 2007 A | 186761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | निदेशक | 16 मई 2007 A | 451900 | 0 | 0 | $0 |
| Charles E Bugg | निदेशक | 18 मार्च 2007 A | 62439 | 0 | 0 | $0 |
| GORDON CARL L | निदेशक | 17 मई 2006 A | 1100000 | 0 | 0 | $0 |
| John A Montgomery | निदेशक | 4 नवमबर 2003 M | 46785 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 15 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 फाइलिंग | 31 जुलाई 2018 | — | प्रारंभिक फाइलिंग | — | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 अप्रैल 2018 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 फाइलिंग | 16 अगस्त 2016 | — | प्रारंभिक फाइलिंग | — | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 फाइलिंग | 23 अक्टूबर 2012 | — | प्रारंभिक फाइलिंग | M&A / बिक्री | SEC |
| Julian C. Baker, Felix J. Baker ×4 फाइलिंग | 13 अक्टूबर 2011 | — | प्रारंभिक फाइलिंग | — | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 फाइलिंग | 20 अगस्त 2007 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 13 अक्टूबर 2005 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 26 फ़रवरी 2004 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 25 फ़रवरी 2004 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 24 फ़रवरी 2004 | — | प्रारंभिक फाइलिंग | — | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 फाइलिंग | 31 अक्टूबर 2003 | — | प्रारंभिक फाइलिंग | — | SEC |
| William W. Featheringill | 14 फ़रवरी 2002 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 54 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1.93% | 125015 NS | 30 अप्रैल 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 1.26% | 1682 NS | 30 अप्रैल 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.67% | 381305 NS | 30 अप्रैल 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.54% | 612341 NS | 30 अप्रैल 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0.41% | 1556494 NS | 30 अप्रैल 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.28% | 364624 NS | 30 अप्रैल 2026 | N-PORT |
| BFOR · ALPS ETF Trust | 0.25% | 59894 NS | 31 मई 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.19% | 213133 NS | 31 मई 2026 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0.19% | 445890 NS | 30 जून 2026 | N-PORT |
| ESSC · Strategy Shares | 0.15% | 4183 NS | 30 अप्रैल 2026 | N-PORT |
| BIB · ProShares Trust | 0.11% | 9271 NS | 31 मई 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.11% | 57134 NS | 30 अप्रैल 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.10% | 81871 NS | 30 अप्रैल 2026 | N-PORT |
| RSSL · Global X Funds | 0.06% | 97958 NS | 30 अप्रैल 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.05% | 806097 NS | 30 अप्रैल 2026 | N-PORT |
| ITWO · ProShares Trust | 0.05% | 10652 NS | 31 मई 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.05% | 1154262 NS | 31 मई 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 96151 NS | 30 अप्रैल 2026 | N-PORT |
| UWM · ProShares Trust | 0.03% | 8331 NS | 31 मई 2026 | N-PORT |
| URTY · ProShares Trust | 0.02% | 8425 NS | 31 मई 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 9529 NS | 31 मई 2026 | N-PORT |
| HDG · ProShares Trust | 0.01% | 212 NS | 31 मई 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 80493 NS | 31 मई 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 74317 NS | 30 अप्रैल 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.00% | 937 NS | 31 मई 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 141645 NS | 31 मई 2026 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 6314 NS | 30 अप्रैल 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 34873 NS | 30 अप्रैल 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.00% | 8956 NS | 30 अप्रैल 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.00% | 129 NS | 31 मई 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 3019 NS | 30 अप्रैल 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VB · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VBK · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | — | — | 15 जुलाई 2026 | दैनिक |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| ITOT · iShares Trust | — | — | 5 अगस्त 2026 | दैनिक |
| IWV · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWO · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWM · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IBB · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| PBE · Invesco Exchange-Traded Fund Trust | — | — | 13 जुलाई 2026 | दैनिक |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 23 जुलाई 2026 | दैनिक |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | 13 जुलाई 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | — | — | 20 जुलाई 2026 | दैनिक |
| ESGV · VANGUARD WORLD FUND | — | — | 30 जुलाई 2026 | दैनिक |
| ISCB · iShares Trust | — | — | 5 अगस्त 2026 | दैनिक |